Download PDF
Thromb Haemost 1999; 82(02): 500-504
DOI: 10.1055/s-0037-1615871
Research Article
Schattauer GmbH

The Role of Genetics in Inhibitor Formation

Joan Cox Gill
1   The Medical College of Wisconsin and The Blood Center of Southeastern Wisconsin, Milwaukee, WI, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Introduction

Treatment of hemorrhages in patients with inherited severe hemophilia A is dependent on transfusion replacement therapy with either plasma-derived or recombinant factor VIII concentrates.1 Hemorrhages become very difficult to treat after inhibitors develop, resulting in significant decreases in qualityof- life and life expectancy.2-6 Strategies to treat hemorrhages in the face of an inhibitor include the use of “bypass” therapy with activated and nonactivated prothrombin complex concentrates, high-dose factor VIII, porcine factor VIII, and recombinant factor VIIa. None of these is as effective as treatment of the noninhibitor patient with factor VIII.2,6 Therefore, several strategies to induce tolerance to factor VIII administration have been attempted, including administration of daily high-dose intravenous infusions of factor VIII concentrate alone, or in combination with, immune-modulating therapy.2,6 These strategies are extraordinarily difficult and expensive and are frequently unsuccessful, particularly when the inhibitor is well established. Thus, the ability to predict which patients are at risk for inhibitor development and to identify factors that predispose to inhibitor development would allow investigation of therapies targeted to prevent the establishment of the inhibitor response or to provide the ability to initiate early and, thus, more effective, immune tolerance induction for those at risk.

 

  • References

  • 1 Gill JC. Therapy of factor VIII deficiency. Semin Thromb Haemost 1993; 19: 1-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Kasper C. Treatment of factor VIII inhibitors. Prog Hemost Thromb 1989; 9: 57-86.
    PubMedGoogle Scholar
  • 3 McMillan CW, Shapiro SS, Whitehurst D. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. Blood 1988; 71: 344-348.
    PubMedGoogle Scholar
  • 4 Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungor T, Krackhardt B, Kornhuber B. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
    CrossrefPubMedGoogle Scholar
  • 5 Sultan Y. for the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost 1992; 67: 600-602.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Lusher J. Management of patients with factor VIII inhibitors. Transfus Med Rev 1987; 1: 123-130.
    CrossrefPubMedGoogle Scholar
  • 7 Schwarzinger I, Pablinger I, Korninger C, Haschke G, Kundi M, Niessner H, Lechner K. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987; 24: 241-245.
    CrossrefPubMedGoogle Scholar
  • 8 Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993; 81: 3332-3335.
    PubMedGoogle Scholar
  • 9 Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort LM. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-464.
    CrossrefPubMedGoogle Scholar
  • 10 de Biasi R, Rocino A, Papa L, Salerno E, Mastrullo L, De Blasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71: 544-547.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Guerois C, Laurian Y, Rothschild C, Parquet-Gernez A, Duclos A, Negrier C, Vicariot M, Fimbel B, Fressinaud E, Fiks-Sigaud M, Derlon A, Berthier A, Gaillard S, Bertrand M. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-218.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White G, Lee M. for the Recombinant Study Group. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 1994; 83: 2428-2435.
    PubMedGoogle Scholar
  • 13 Lusher J, Arkin S, Abildgaard C, Schwartz RS. for the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993; 328: 453-459.
    CrossrefPubMedGoogle Scholar
  • 14 McMillan CW, Shapiro SS, Whitehurst D, Hoyer LW, Rao AV, Lazerson J. The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood 1988; 71: 344-348.
    PubMedGoogle Scholar
  • 15 Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In : Aledort LM. ed. Inhibitors to Coagulation Factors. Plenum Press; New York: 1995: 35.
    Google Scholar
  • 16 Peerlinck K, Arnout J, Di Giambattista M, Gilles JG, Laub R, Jacquemin M, Saint-Remy JM, Vermylen J. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost 1997; 77: 80-86.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J, Smit C, Strengers PFW. for the Dutch Haemophilia Study Group. A sudden increase in factor VIII inhibitor development in multitransfused haemophilia A patients in The Netherlands. Blood 1993; 81: 2180-2186.
    PubMedGoogle Scholar
  • 18 Bray GL, Kroner BL, Arkin S, Aledort LM, Hilgartner M, Eyster ME, Ragni MV, Goedert JJ. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus Type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42: 375-379.
    CrossrefPubMedGoogle Scholar
  • 19 European Study Group of Factor VIII Antibody. Development of factor VIII antibody in haemophilic monozygotic twins. Scan J Haematol 1979; 23: 64-68.
    PubMedGoogle Scholar
  • 20 Shapiro SS. Genetic predisposition to inhibitor formation. Prog Clin Biol Res 1984; 150: 45-55.
    PubMedGoogle Scholar
  • 21 Frommel D, Allain JP. Genetic predisposition to develop factor VIII antibody in classic hemophilia. Clin Immuno Immunopathol 1977; 8: 34-38.
    CrossrefPubMedGoogle Scholar
  • 22 Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (Factor VIII:C deficiency). Blood 1984; 63: 451-456.
    PubMedGoogle Scholar
  • 23 Tinlin S, Webster S, Giles AR. The development of homologous (canine/anti-canine) antibodies in dogs with haemophilia A (factor VIII deficiency): a ten-year longitudinal study. Thromb Haemost 1993; 69: 21-24.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, Olek K, Tuddenham EGD, Oldenburg J. Haemophilia A. Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74: 1402-1406.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Tuddenham EGD, McVey JH. The genetic basis of inhibitor development in haemophilia A. Haemophilia 1998; 4: 543-545.
    CrossrefPubMedGoogle Scholar
  • 26 Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, Ketterling RP, Kazazian JJ, Negrier C, Vinciguerra C, Gitschier J, Goossens M, Girodon E, Ghanem M, Plassa F, Lavergne JM, Vidaud M, Costa JM, Laurian Y, Lin S, Lin S, Shen M, Lillicrap D, Taylor SAM, Windsor S, Valleix SB, Nafa K, Sultan Y, Delpech M, Vnencak-Jones CL, Phillips III JA, Ljung RCR, Koumbarelis E, Gialeraki A, Mandalaki T, Jenkins PV, Collins PW, Pasi J, Goodeve AC, Peake IR, Preston FE, Schwartz M, Scheibel E, Ingerslev J, Cooper DN, Millar DS, Kakkar VV, Giannelli F, Naylor JA, Tizzano EF, Baiget M, Domenech M, Altisent C, Tusell J, Beneyto M, Lorenzo JI, Gaucher C, Mazurier C, Peerlinck K, Matthijs G, Cassiman JJ, Vermylen J, Mori PG, Acquila M, Caprino D, Inaba J. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 1995; 86: 2206-2212.
    PubMedGoogle Scholar
  • 27 Gill JC, Lessinger C, Kasper C, Sexhauer C, Inwood M, Cohen A. for the HRS Inhibitor Registry Investigators. Hemophilia inhibitors in the 80s and 90s: a first look at the Hemophilia Research Society Inhibitor Registry. Blood 1996; 88: 330a.
    PubMedGoogle Scholar
  • 28 Lavergne JM, Meyer D, Reisner H. Characterization of human anti-factor VIII antibodies purified by immune complex formation. Blood 1976; 48: 931-939.
    PubMedGoogle Scholar
  • 29 Shapiro SS. Characterization of factor VIII antibodies. Ann N Y Acad Sci 1975; 240: 350-361.
    CrossrefPubMedGoogle Scholar
  • 30 Allain JP, Frommel D. Antibodies to factor VIII: specificity and kinetics of iso- and hetero-antibodies in hemophilia A. Blood 1974; 44: 313-322.
    PubMedGoogle Scholar
  • 31 Fulcher CA, De Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclasss and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-1480.
    PubMedGoogle Scholar
  • 32 Gilles JG, Armout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophilic patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452.
    PubMedGoogle Scholar
  • 33 Schultz CL, Coffman RL. Control of isotype switching by T cells and cytokines. Curr Opin Immunol 1991; 3: 350-354.
    CrossrefPubMedGoogle Scholar
  • 34 Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S, Zurawski G, de Waal Malefyt R, de Vries JD. Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1998; 90: 3730.
    PubMedGoogle Scholar
  • 35 Larocque R, Robinson MA. Diversity in the human T cell receptor beta chain. Hum Immunol 1996; 48: 3-11.
    CrossrefPubMedGoogle Scholar
  • 36 Shevach EM, Rosenthal AS. Function of macrophages in antigen recognition by guinea pig T lymphocyptes. II. Role of the macrophage in the regulation of genetic control of the immune response. J Exp Med 1973; 138: 1213-1229.
    CrossrefPubMedGoogle Scholar
  • 37 Mayr WR, Lechner K, Niessner H, Pabinger-Fasching I. HLA-DR and factor VIII antibodies in hemophilia A. Thromb Haemost 1984; 51: 293.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Lippert LE, Fisher LM, Schook LB. Relationship of major histocompatibility complex class II genes to inhibitor antibody formation in hemophilia A. Thromb Haemost 1990; 64: 564-568.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Aly AM, Aledort LM, Lee TD, Hoyer LW. Histocompatibility antigen patterns in haemophilic patients with factor VIII antibodies. Br J Haematol 1990; 76: 238-241.
    CrossrefPubMedGoogle Scholar
  • 40 Hay CRM, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, Colvin BT, Hill FGH, Preston FE, Peake IR. for the UKHC-DO Inhibitor Working Party. HLA class II profile. A weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997; 77: 234.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Oldenburg J, Picard J, Schwaab R, Brackman HH, Tuddenham EGD, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997; 77: 238-242.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Theofilopoulos A. The basis of autoimmunity: part II. Genetic predisposition. Immunol Today 1995; 16: 150-159.
    CrossrefPubMedGoogle Scholar
  • 43 Hershey GK, Friedrich M, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 1720-1725.
    CrossrefPubMedGoogle Scholar